drugset / Trial / NCT07284745

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

NCT07284745

Phase 3 Not yet recruiting 176 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.

Timeline

Start
2026-09-11
Primary completion
2029-07-05
Completion
2029-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Trospium Small molecule
Subject Xanomeline Small molecule